000179137 001__ 179137
000179137 005__ 20240229145534.0
000179137 0247_ $$2doi$$a10.3390/ijms23042337
000179137 0247_ $$2pmid$$apmid:35216457
000179137 0247_ $$2pmc$$apmc:PMC8879842
000179137 0247_ $$2ISSN$$a1422-0067
000179137 0247_ $$2ISSN$$a1661-6596
000179137 0247_ $$2altmetric$$aaltmetric:123701529
000179137 037__ $$aDKFZ-2022-00493
000179137 041__ $$aEnglish
000179137 082__ $$a540
000179137 1001_ $$aSchwarzbich, Mark-Alexander$$b0
000179137 245__ $$aPre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation.
000179137 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2022
000179137 3367_ $$2DRIVER$$aarticle
000179137 3367_ $$2DataCite$$aOutput Types/Journal article
000179137 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1647611168_25816
000179137 3367_ $$2BibTeX$$aARTICLE
000179137 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179137 3367_ $$00$$2EndNote$$aJournal Article
000179137 520__ $$aWeight loss and metabolic activity influence outcome after allogeneic stem cell transplantation (alloSCT). This study evaluates pre-conditioning Leptin, a peptide hormone involved in metabolism and immune homeostasis, as a prognostic factor for survival, relapse and non-relapse mortality (NRM) following alloSCT. Leptin serum levels prior to conditioning were determined in a cohort of patients transplanted for various hematologic malignancies (n = 524) and correlated retrospectively with clinical outcome. Findings related to patients with acute leukemia (AL) from this sample were validated in an independent cohort. Low pre-conditioning serum Leptin was an independent prognostic marker for increased risk of relapse (but not of NRM and overall mortality) following alloSCT for AL of intermediate and advanced stage (beyond first complete remission). Multivariate analysis revealed a hazard ratio (HR) for relapse of 0.75 per log2 increase (0.59-0.96, p = 0.020). This effect was similar in an independent validation cohort. Pre-conditioning serum Leptin was validated as a prognostic marker for early relapse by fitting the multivariate Cox model to the validation data. Pre-conditioning serum Leptin levels may serve as an independent prognostic marker for relapse following alloSCT in intermediate and advanced stage AL patients. Prospective studies are required to prove whether serum Leptin could be used for guiding nutritional intervention in patients with AL undergoing alloSCT.
000179137 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000179137 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179137 650_7 $$2Other$$aALL
000179137 650_7 $$2Other$$aAML
000179137 650_7 $$2Other$$aAdiponectin
000179137 650_7 $$2Other$$aacute lymphoblastic leukemia
000179137 650_7 $$2Other$$aacute myeloid leukemia
000179137 650_7 $$2Other$$aallogeneic stem cell transplantation
000179137 650_7 $$2Other$$abody mass index
000179137 650_7 $$2Other$$aleptin
000179137 650_7 $$2Other$$arelapse
000179137 650_7 $$2Other$$asurvival
000179137 7001_ $$0P:(DE-He78)e1550b77d7eed3425c8e245362b45281$$aDai, Hao$$b1
000179137 7001_ $$00000-0003-3116-473X$$aKordelas, Lambros$$b2
000179137 7001_ $$aBeelen, Dietrich W$$b3
000179137 7001_ $$00000-0002-8543-5016$$aRadujkovic, Aleksandar$$b4
000179137 7001_ $$aMüller-Tidow, Carsten$$b5
000179137 7001_ $$aDreger, Peter$$b6
000179137 7001_ $$00000-0002-0387-1640$$aLuft, Thomas$$b7
000179137 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms23042337$$gVol. 23, no. 4, p. 2337 -$$n4$$p2337$$tInternational journal of molecular sciences$$v23$$x1422-0067$$y2022
000179137 909CO $$ooai:inrepo02.dkfz.de:179137$$pVDB
000179137 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e1550b77d7eed3425c8e245362b45281$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000179137 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000179137 9141_ $$y2022
000179137 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000179137 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000179137 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000179137 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000179137 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000179137 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000179137 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-09-04T08:27:04Z
000179137 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-09-04T08:27:04Z
000179137 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-09-04T08:27:04Z
000179137 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-25
000179137 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-25
000179137 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2021$$d2022-11-25
000179137 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000179137 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000179137 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000179137 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000179137 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2022-11-25
000179137 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J MOL SCI : 2021$$d2022-11-25
000179137 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000179137 980__ $$ajournal
000179137 980__ $$aVDB
000179137 980__ $$aI:(DE-He78)C020-20160331
000179137 980__ $$aUNRESTRICTED